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This commentary discusses the intersection of human ovarian and somatic aging. It argues for re-contextualizing
estrogen’s role in and impact on ovarian aging and, more broadly, on women’s health, considering in particular the
importance of timing, dose, and the broader endocrine milieu. Distinguishing between current clinical needs and
optimizing women’s future options, the paper outlines an approach to broadening the research agenda to better
understand the role of ovarian aging in supporting the metabolic demands of longevity. Three overarching issues
important to consider explicitly as we pursue research on the health correlates of reproductive aging are discussed,
including implications of a lifespan approach, population diversity, and selection bias.
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The papers in this section address the intersec-
tion of human ovarian and somatic aging and
discuss emerging evidence that suggests a need to
re-contextualize estrogen’s role in and impact on
ovarian aging and, more broadly, women’s health.
As articulated in these papers—timing matters, dose
matters, and the broader endocrine milieu matters.
It also matters whether our goal is to address cur-
rent health needs with currently available options,
for example, the problem that confronts physicians
endeavoring to alleviate a woman’s suffering with
currently available options, or to optimize the op-
tions women may have in 10 or 20 years time.
To achieve the latter goal of optimizing future
options, more explicit research efforts are needed:
(1) To develop an integrative understanding of the
role of estrogen in physiology and health at
different points across the life course;
(2) To place the physiologic impact of estrogen
in the context of other critical and bioac-
tive reproductive hormones (e.g., follicle-
stimulating hormone [FSH]);
(3) To weigh estrogen’s importance relative to
other aspects of physiology and in the context
of environmental insults.
This commentary reflects on the contributions
of three of the workshop presentations published
here as well as on comments made in other pre-
sentations during this workshop session. I elaborate
on three overarching issues important to consider
more explicitly as we pursue research on the health
correlates of reproductive aging—implications of a
lifespan approach, population diversity, and selec-
tion bias.
An important question raised in the context
of this session was whether an adaptive role of
a low estrogen state might be articulated for the
postmenopausal period as has been proposed for
the period of lactation.1,2 For example, a bio-
logic advantage has been proposed for hot flashes
that benefits the newborn and for activation of
the hypothalamic–pituitary–ovarian (HPO) axis to
attenuate maternal stress responses and enhance
metabolic and immune responses.1–3 Presenters
questioned, however, whether the necessary com-
pensatory mechanisms are established for a low es-
trogen state in the postmenopause to offset the neg-
ative consequences of loss of bone and increases in
arterial tone, C-CRP, and LDL-C, etc. This excellent
question requires more exploration.
Aging ova and the known exponentiation of
risk of chromosomal disruptions in pregnancies af-
ter age 404,5 may be the most parsimonious bio-
logic explanation for ovarian senescence. Selection
factors that enhance longevity may well not have
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ovarian origins. Alternatively, ovarian senescence
may promote healthy aging by reducing the en-
ergy demands of repeated pregnancy and continued
menstruation.
Workshop presenters argue that a low estrogen
state is also adaptive in prolonging birth inter-
vals and reducing fertility during periods of food
scarcity. I noted with particular interest graphs re-
produced from Emory Thompson et al.6 comparing
fertility and survivorship in various populations and
species. These graphs suggested that the !Kung, with
the narrowest fertility curve and limited reproduc-
tion after age 35, experience a survivorship of 50% at
age 60–64 and of 20% at age 70, which is remarkable
in a subsistence population. We might wish to con-
sider further what this relationship suggests about
environmentally moderated reproductive function
and healthy aging.
Although not an expert on the evolutionary bi-
ology of aging literature, I would nonetheless ask
whether we adequately understand the metabolic
demands of longevity or the adaptive immune re-
sponses that promote longevity. From an evolu-
tionary perspective we might inquire about the
metabolic demands of taking on increased responsi-
bility as a gatherer,7 how stamina or strength is best
preserved, especially in the context of aging physi-
ologic systems, and whether the relative increase in
androgens, in fact, promotes survival.
The controversy in women’s health regarding
whether the postmenopausal low estrogen state
should be construed as a deficiency state or an
adaptive response to the demands of aging was
highlighted by an analogy, and the critique of
that analogy, made during the workshop between
menopausal women and the witch in Hansel and
Gretel. It was suggested that the physique of the old
crone may be easily explained when framed through
the lens of estrogen deprivation. Reconsidering this
analogy, we are obliged to consider what alternative,
perhaps environmental, explanations might be pro-
vided for this old woman’s condition. Is her frailty
fully determined by her postmenopausal state or
might somatic aging contribute? The story, being
set in the context of famine and dire poverty, sug-
gests a potential role for malnutrition while vita-
min D deficiency might also play a role given a
life spent residing within the deep dark wood. The
witch is, after all, a hardy survivor—the children’s
mother is dead (perhaps a maternal death) and their
stepmother too does not survive the end of the
story.
Alternatively, it may prove more productive to
consider the differences between applying a con-
struct of adaptation versus adjustment. If we can
accept a value in limiting the reproductive period
and the consequent necessity of a transition in the
reproductive hormone milieu, how do we concep-
tualize a period of adjustment and what do we
know about generating the optimal postreproduc-
tive physiologic state. The portrayal of aging as a
state of menopausal estrogen deprivation can not in
the end suffice, because the postmenopausal state is
universal for all surviving women, yet decrepitude
is not, and a place must be created for incorporat-
ing the fact of healthy aging. We have, perhaps, in
much of our research failed to properly delineate
bothersome symptoms of transition from chronic
morbidity. Using the analogy of the stages of grief,
we may need to consider more thoughtfully what
constitutes normative adjustment versus an unre-
solved or morbid response.
Clinicians confront the suffering of a specific por-
tion of the postmenopausal population. Hormone
therapy (HT) helps ameliorate suffering. Yet the pa-
tient represents just one, relatively small, portion
of the population distribution. Our scientific task
is to consider more rigorously what combination
of baseline risk, environmental modifiers, and pat-
terns of reproductive aging are most indicative of
risk.
One important lesson of the paradigm shift in
the post-Women’s Health Initiative (WHI) era8
is the importance of adopting a life course per-
spective and of balancing multiple competing risks
within populations and individuals. Pinkerton and
Stovall9 consider in careful detail the emerging clin-
ical evidence for a differential impact of HT expo-
sure given age at initiation and underlying disease
status, particularly in the context of cardiovascu-
lar disease and dementia. The WHI and other data
presented in this paper suggest the possibility of crit-
ical windows for intervention. Data emerging from
the longitudinal cohort studies of midlife women,
discussed by Ferrell and Sowers,10 also suggest that
the midlife represents a critical period, setting the
stage for women’s long-term health across multi-
ple dimensions. Traub and Santoro11 review the
complex interrelationships that occur in the aging
process between changes in the HPO axis and the
164 Ann. N.Y. Acad. Sci. 1204 (2010) 163–168 c© 2010 New York Academy of Sciences.
Harlow Commentary
somatotrophic axis. What remains unclear is the ex-
tent to which physiologic changes leading to cardio-
vascular disease, for example, originate in ovarian
senescence or simply track with it. Further concep-
tualization is needed to articulate the specific mean-
ing of a critical window as a period of adjustment,
adaptation, or onset of decline. Is it that women
must optimize opportunities to safely traverse this
period of adjustment, or is it a window after which
there is no safe haven? In either case, the unanswered
questions include: how early might intervention be
warranted and in whom?; what are the critical mark-
ers of preexisting abnormality?; and what might the
risks of intervention be to women with a preexisting
condition?
The epidemiologic literature generally supports
an association between earlier age at menopause
and mortality (all-cause and cardiovascular dis-
ease),12–16 with some evidence supporting an
association also with cardiovascular disease inci-
dence.17,18 However, these data are not fully consis-
tent regarding the relative importance of premature
menopause and surgical menopause in defining
these risks. The extent to which risk in the latter
subgroup is a consequence of early and/or abrupt
ovarian senescence versus a consequence of the un-
derlying health issue that led to the premature/early
menopause/hysterectomy is underinvestigated and
not resolved. Similarly, our understanding of the
role of poor health in advancing age at menopause
in general remains inadequate. Yet, evidence contin-
ues to build suggesting that poor health (diabetes,
depression, heart disease) is associated with, or leads
to, earlier age at menopause.19–23 Furthermore, sev-
eral factors including body mass index, smoking,
and socioeconomic status, are common correlates
of menopause, menstrual characteristics across the
lifespan, and mortality.19,20,22,24–26 Addressing these
interrelationships will be critical to evaluating the
timing of risk onset and the extent to which ovarian
senescence does, or does not, play a causal role is
defining women’s risk status.
Ferrell and Sowers10 describe the longitudinal
epidemiologic studies characterizing reproductive
aging in population-based samples and discuss their
contribution to our understanding of reproduc-
tive aging and ovarian senescence in population-
based samples of women. These studies typically
capture all or part of the lifespan relevant to the
“critical window” hypothesis and provide insights
into factors associated with population variabil-
ity in reproductive aging and, frequently, the dy-
namic interface between reproductive and somatic
aging.
Recent data from these studies document the rel-
atively late occurrence of the decline in estrogen in
relation to other endocrine changes characteristic of
the reproductive aging process including decline in
anti-mullerian hormone (AMH), decline in inhibin
and rise in FSH. This fact suggests the potential
for more precisely delineating the timing of specific
physiologic changes of somatic aging in relation to
specific physiologic changes of reproductive aging
as well as their relevant endocrine correlates. These
authors specifically point to the interdependence
of reproductive and somatic aging, stressing the
importance of teasing out the impact of aging (i.e.,
aging of the hypothalamic-pituitary axis) on signals
classically defined as those of reproductive aging
(e.g., FSH).
Traub and Santoro11 summarize the emerging ev-
idence of the role of estrogen in supporting the func-
tional integrity of the somatotrophic axis during the
menstrual cycle, its association with declines in in-
sulin growth factor with aging and its relationship to
cardiovascular risk and bone mineral density. They
also summarize the evidence related to aging of the
adrenal axis and its complex relationship to ovar-
ian aging and chronic disease. They argue that low
DHEAS levels have been associated with a range
of health issues including cardiovascular disease,
depression, and diabetes that previously have fre-
quently been attributed to menopause and estrogen
deficiency.
Of critical importance here is the need to
establish:
(1) What role a woman’s status at the onset of the
menopausal transition plays in defining her
risk profile;
(2) At what step in the reproductive aging process
decrements in physiologic function are or are
not initiated or accelerated; and
(3) Whether patterns or rates of change in repro-
ductive function matter to health and well-
being at the end of the transition.
Once these questions are answered, we may per-
haps have an answer to the question “How impor-
tant then is estrogen really?”
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A lifespan perspective
The critical window hypothesis has focused atten-
tion on the importance of midlife to health later in
life. Yet, the midlife spans about one-fifth of a long-
lived individual’s lifespan, and normal menopause
itself may occur across a 20-year span from approx-
imately age 40–60. There is also substantial variabil-
ity in the duration of the menopausal transition,
especially the early transition. Longitudinal studies
of reproductive age and midlife women have docu-
mented that poor risk profiles for a range of condi-
tions, including low bone mineral density, often are
established prior to the onset of the menopausal
transition.26–28 We have yet to undertake studies
with sufficient numbers of women enrolled in their
peak reproductive or true late reproductive stage to
provide a clear understanding of how baseline risk
status segregates women’s experience as they transi-
tion through the menopause or this presumed crit-
ical window. Thus, it is difficult to know whether
the risk we observe at later life stages is dominated
by baseline risk, for example, the failure to deposit
adequate bone to weather the transition period.
Most current studies enroll prevalent cohorts, that
is women still menstruating, thus the at-risk women
are frequently excluded.29,30
Although growing, the literature relating men-
strual characteristics across the lifespan to other pa-
rameters of health and disease remains somewhat
limited. Nonetheless, emerging data suggest that
reproductive physiology tracks in particular ways
across the life course and that the ovarian/somatic
interlinkage also tracks in particular ways across the
life course. For example,
(1) timing of menarche is associated with chronic
disease risk but is not clearly correlated with
peak reproductive menstrual characteristics31
or with age at menopause;
(2) long-normal menstrual cycles (30–31 days) are
associated with higher fecundity32 and later
age at menopause31;
(3) menstrual cycle length and variability are as-
sociated with chronic disease risk25; and
(4) timing of menopause is associated with
chronic disease risk and mortality.13,14,16
Several questions about lifelong trajectories and
the interlinkage between reproductive function and
health across these trajectories remain, including:
(1) careful specification of the timing of cardio-
vascular insults and explication of what deter-
mines the ability of the cardiovascular system
to weather the endocrine shift that is charac-
teristic of menopause;
(2) explication of the health benefits of being
postmenopausal, for example in terms of en-
ergy conservation, the importance of andro-
gens to maintaining musculoskeletal health
and whether there may be an evolutionary ad-
vantage to observed shifts in metabolism and
to metabolic syndrome;
(3) what the relative health advantage of an osteo-
porotic versus osteoarthritic profile may be.
Learning from population variability
To date, the primary focus of the longitudinal
population cohort studies of midlife women has
been to describe the typical or dominant pattern
of reproductive aging. However, these studies have
the potential to provide important information on
common variants from this typical or dominant pat-
tern, as well as on genetic, behavioral, and/or envi-
ronmental factors that might be associated with the
population distribution of variant patterns. Increas-
ing scientific focus on common variants of the re-
productive aging process may facilitate understand-
ing of the biologic tradeoffs that accompany these
different trajectories and may provide insights into
differential patterns of disease risk.
Gorrindo et al.33 have created an algorithm for
typing women’s lifetime menstrual histories into
five categories: stable, stable but with greater vari-
ability, oscillating/erratic cycle lengths with a down-
ward trend in cycle length over time, oscillat-
ing/erratic cycle lengths with a no downward trend
in cycle length over time, and highly erratic. We
are currently working on an approach for modeling
cycle variability before and after the menopausal
transition that allows for uncertainty in the typing
of an individual woman’s profile and permits us to
relate profile types to covariates in the context of a
regression model (Elliott, Huang, and Harlow, sub-
mitted for publication). Pinkerton and Stovall9 rec-
ommend increased focus on the subpopulation of
women with surgical menopause. Oligomenorrheic
women are another subgroup that warrants further
research focus. As we learn more about variability
in the reproductive aging process, it may be possible
to define important subgroups in relationship to the
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probability of healthy aging and to clarify what the
evolutionary advantage might be for each different
population subgroup.
Selection and bias
In evaluating studies, whether they involve clinical
populations or longitudinal population based sam-
ples, increased attention to selection factors and es-
timating bias is warranted. As noted earlier, most
longitudinal cohort studies enroll prevalent cohorts
with eligibility defined by presence of menses, ex-
cluding (or truncating) women who have already
achieved their final menstrual period (FMP) at the
time of enrollment. We have shown through sim-
ulations that bias can be substantial and standard
errors severely underestimated in a naı̈ve analysis
which ignores this left truncation and/or left censor-
ing and that this bias increases with increasing age
of the prevalent cohort (Cain et al., submitted for
publication). Research attempting to define critical
thresholds for chronic disease risk may need to pay
particular attention to issues of selection and bias
if presence of underlying disease is associated with
increased likelihood of being postmenopausal at a
given age. Issues of generalizability, or lack thereof,
may lead to mis-estimation of the association be-
tween reproductive and somatic aging. As noted by
Ferrell and Sowers10 most of the cohort studies have
captured relatively few hysterectomized women or
women who are early or late transitioners.
Additional selection issues can arise when data are
analyzed prior to all members of the cohort achiev-
ing the FMP or other markers of the menopausal
transition. Current estimates of the timing of AMH
decline, for example, reflect results from the early
completers in the studies from which they are de-
rived. Thus, published estimates of average time to
FMP following AMH decline may well change as
more women in these studies reach transition and
menopause.
In summary, the papers in this section have
raised important questions about the interrelation-
ships between ovarian and somatic aging. Although
knowledge of these interrelationships has increased
in the last decade, a fundamental set of questions
remains unanswered, that is to what extent, or in
what context, is
(1) ovarian aging correlated with somatic aging,
that is, it is an early marker of aging and should
inform timely interventions;
(2) ovarian aging a trigger for somatic aging, con-
sistent with the critical window hypothesis,
such that our clinical goal should be to pro-
long ovarian function; or,
(3) ovarian aging triggered by somatic aging or
underlying disease such that our clinical goal
should be to treat the somatic disease.
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